Company Valeo Pharma Inc.

VPH

CA91915B1085

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 19:37:44 26/06/2024 BST			5-day change	1st Jan Change
0.115 ^CAD	-8.00%		-11.54%	-36.11%

06-18	Valeo Pharma Names Chief Development Officer; Up Nearly 22%	MT
06-18	Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors	CI

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Number of employees: 80

CAD in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals and Hospital Specialty Products 100.0 %	28	100.0 %	54	100.0 %	+94.31%

CAD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	28	100.0 %	54	100.0 %	+94.31%

Managers	Title	Age	Since
Steven Saviuk FOU	Founder	65	26/03/03
Pascal Tougas DFI	Director of Finance/CFO	-	11-19
Nelly Komari CTO	Chief Tech/Sci/R&D Officer	-	31/05/21
Frédéric Dumais IRC	Investor Relations Contact	-	31/05/19
Pierre Ecclestone PRN	Corporate Officer/Principal	-	31/07/23
Kyle Steiger PRN	Corporate Officer/Principal	-	29/08/22
David Newell SAM	Sales & Marketing	-	31/10/11
Nathalie Therrien LAW	General Counsel	56	24/01/16
Guy-Paul Allard LAW	General Counsel	56	31/03/16
Helen Saviuk PRN	Corporate Officer/Principal	71	31/12/07

Members of the board	Title	Age	Since
Richard MacKay CHM	Chairman	89	24/07/18
Steven Saviuk FOU	Founder	65	26/03/03
Ali Moghaddam PRN	Corporate Officer/Principal	-	03-21
Marc Léger BRD	Director/Board Member	65	26/04/22
Richard Lajoie BRD	Director/Board Member	-	11-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	98,675,427	52,181,062 ( 52.88 %)	0	52.88 %

Name	Equities	%	Valuation
MANITEX CAPITAL INC. 27.62 %	27,247,877	27.62 %	2 M $
Richard MacKay 16.44 %	16,222,751	16.44 %	1 M $
Investissement Québec 7.240 %	7,142,857	7.240 %	442 857 $
Steven Saviuk 3.882 %	3,829,890	3.882 %	237 453 $
Luc Mainville 3.082 %	3,041,055	3.082 %	188 545 $
Helen Saviuk 2.603 %	2,568,324	2.603 %	159 236 $
Marc Léger 2.363 %	2,331,414	2.363 %	144 548 $
Simcor Canada Holdings, Inc. 1.717 %	1,694,145	1.717 %	105 037 $
Jeffrey Skinner 1.421 %	1,402,150	1.421 %	86 933 $
Nathalie Therrien 1.377 %	1,358,369	1.377 %	84 219 $

Valeo Pharma, Inc.

16667 Hymus Boulevard

H9H 4R9, Kirkland

+514-694-0150

http://www.valeopharma.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.115 CAD

Average target price

0.45 CAD

Spread / Average Target

+291.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
VALEO PHARMA INC.	-36.11%	8.28M
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.76%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.00%	246B
ROCHE HOLDING AG	+2.62%	225B
NOVARTIS AG	+12.78%	218B
AMGEN INC.	+8.61%	168B

Other Pharmaceuticals